‘Disappointing’ ViaCyte data raise questions about future of company’s attempted diabetes cure

Over the last 20 years, ViaCyte — under one name or another — has pursued one of the most audacious goals in biotech: a cure for type 1 diabetes.

The company’s plan was to take lab-grown stem cells and turn them into the insulin-producing cells that are destroyed in T1D...

Click to view original post